338399-29-4

Basic information

• Product Name: 5-ACETYL-1-BENZYL-2,4(1H,3H)-PYRIMIDINEDIONE
• Synonyms: 5-ACETYL-1-BENZYL-2,4(1H,3H)-PYRIMIDINEDIONE;5-acetyl-1-benzyl-1,2,3,4-tetrahydropyrimidine-2,4-dione
• CAS NO: 338399-29-4
• Molecular Formula: C₁₃H₁₂N₂O₃
• Molecular Weight: 244.25
• Mol File: 338399-29-4.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-ACETYL-1-BENZYL-2,4(1H,3H)-PYRIMIDINEDIONE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-ACETYL-1-BENZYL-2,4(1H,3H)-PYRIMIDINEDIONE(338399-29-4)
• EPA Substance Registry System: 5-ACETYL-1-BENZYL-2,4(1H,3H)-PYRIMIDINEDIONE(338399-29-4)

Safety Data

• Hazardous Substances Data: 338399-29-4(Hazardous Substances Data)

Upstream product

• 6214-65-9 5-acetyluracil 
• 100-39-0 benzyl bromide 
• 1202696-94-3 1-Benzyl-5-ethynyluracil 
• 1434536-01-2 1-N-benzyl-5-[2-(triphenylgermyl)acetyl]uracil 

Downstream Products

• 338399-30-7 3-(4-fluorobenzyl)-5-acetyl-1-benzyluracil 

Relevant articles and documents

Synthesis and reduction reactions of pyridones and 5-acyl-2-methoxypyridines

The synthesis of a series of pyridones, from their 2-hydroxypyridine or 2-methoxypyridine precursors, is described, along with studies into their reductions to saturated heterocycles. A number of 5-acylpyridones were prepared and were evaluated as substrates for asymmetric transfer hydrogenation prior to conversion to saturated heterocycles. The enantioselective reduction of 5-acetyl-1-benzylpyrimidine-2,4(1H,3H)-dione is also described.

DIKETO ACIDS WITH NUCLEOBASE SCAFFOLDS: ANTI-HIV REPLICATION INHIBITORS TARGETED AT HIV INTEGRASE IN COMBINATION THERAPY

A new class of diketo acids constructed on nucleobase scaffolds, designed as inhibitors of HIV replication through inhibition of HIV integrase, is described. These compounds are useful in the prevention or treatment of infection by HFV and in the treatmen

Diketo acids on nucleobase scaffolds as inhibitors of Flaviviridae

A new class of diketo acids constructed on nucleobase scaffolds, designed as inhibitors of HCV replication through inhibition of HCV NS5B RNA polymerase, is described. These compounds are useful in the prevention or treatment of infection by HCV and in th